1. Home
  2. ACB vs NERV Comparison

ACB vs NERV Comparison

Compare ACB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$3.72

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.24

Market Cap

231.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
NERV
Founded
2013
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.3M
231.1M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ACB
NERV
Price
$3.72
$4.24
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.50
AVG Volume (30 Days)
1.5M
124.0K
Earning Date
06-17-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
$6.31
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$1.93
52 Week High
$6.67
$12.46

Technical Indicators

Market Signals
Indicator
ACB
NERV
Relative Strength Index (RSI) 54.25 40.82
Support Level $3.27 $3.87
Resistance Level $3.91 $4.25
Average True Range (ATR) 0.13 0.33
MACD -0.06 -0.08
Stochastic Oscillator 3.75 1.31

Price Performance

Historical Comparison
ACB
NERV

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: